GSK won an expanded FDA approval for its RSV vaccine in younger adults, a regulatory win that could reignite sales momentum. The FDA also issued draft guidance streamlining biosimilar development, a move that could cut PK study costs by up to 50% and reshape competitive dynamics across biologics. Meanwhile, Immutep's LAG-3 checkpoint inhibitor stumbled in lung cancer, and AI diagnostics startup Waiv spun out from Owkin with $33M in funding.
Top Stories
GSK Wins FDA Approval to Expand RSV Vaccine to Younger Adults
The FDA has broadened the indication for GSK's Arexvy RSV vaccine to include younger adults, according to BioPharma Dive. The expanded approval comes at a critical time for vaccine manufacturers navigating a challenging regulatory environment and could help reverse flattening sales trends following the shot's initially strong commercial launch. This signals the FDA's growing confidence in RSV vaccine safety profiles across broader age ranges.
New FDA Guidance Could Elevate Pharma's Biosimilar Market
The FDA issued draft guidance that would streamline biosimilar development by reducing clinical pharmacokinetic testing requirements when scientifically justified, potentially cutting PK study costs by up to 50% — roughly $20 million per program, Fierce Pharma reported. The revision also allows developers to rely on clinical data from comparator products approved outside the U.S., removing the need for additional three-way comparison studies. With biologics representing just 5% of prescriptions but 51% of U.S. drug spending, the guidance could meaningfully expand the competitive runway for major biosimilar players including Amgen, Pfizer, and Sandoz — though analysts caution that patent thickets, rebate structures, and PBM dynamics remain significant barriers to realizing full cost savings.
Immutep's LAG-3 Checkpoint Inhibitor Fails Phase 3 Lung Cancer Study
Endpoints News reports that Immutep's LAG-3 checkpoint inhibitor failed to meet endpoints in a Phase 3 lung cancer trial, casting further doubt on whether LAG-3 can emerge as the third major checkpoint target after PD-1 and CTLA-4. The oncology field had high hopes for LAG-3 following the FDA's 2022 approval of the first LAG-3 drug, but subsequent development programs have struggled to replicate early promise. This setback suggests the checkpoint inhibitor landscape may remain dominated by existing mechanisms for the foreseeable future.
Grail CEO Steps Down Following Clinical Trial Setback
Grail's chief executive has resigned after the cancer screening company experienced a trial disappointment, according to STAT. The leadership change comes as the company navigates both clinical development challenges and the aftermath of its contentious acquisition by Illumina. The move suggests Grail's board is seeking fresh strategic direction following setbacks to its multi-cancer early detection platform.
AI Diagnostics Startup Waiv Spins Out From Owkin With $33M in Funding
Waiv, the former diagnostics division of AI biotech Owkin, has completed its spinout as an independent company with $33 million in funding to advance AI-enabled cancer testing technologies, MedCity News reported. Co-founder and CEO Meriem Sefta said the separation allows Waiv to pursue its own growth strategy while continuing to serve both clinical settings and drug research applications. This signals increasing investor appetite for AI-powered precision diagnostics as a standalone business model separate from therapeutic development.
Danish Biotech Gubra Plans Roivant-Style Incubation Model for Obesity Pipeline
The 300-employee Danish biotech Gubra is evolving beyond its existing obesity partnerships to adopt an incubation-focused business model similar to Roivant Sciences, reports Endpoints News. The 18-year-old company aims to leverage its obesity drug development expertise to create and spin out multiple focused entities as its partnered programs advance. The move suggests confidence in the durability of the obesity therapeutics market and reflects growing sophistication in European biotech business models.
EMA Safety Committee Issues Aseptic Meningitis Warning for Chikungunya Vaccine Ixchiq
The European Medicines Agency's Pharmacovigilance Risk Assessment Committee recommended updating the product information for chikungunya vaccine Ixchiq to reflect evidence of aseptic meningitis risk, according to the agency's March meeting highlights. The safety signal assessment addresses a known risk that requires clearer communication to prescribers and patients. This highlights ongoing post-approval surveillance challenges for newly launched vaccines in emerging disease areas.
What to Watch
- RSV vaccine market expansion — GSK's label expansion could trigger competitive responses from Pfizer and other RSV vaccine developers seeking to broaden their own age indications, potentially accelerating market penetration beyond the initial elderly population.
- LAG-3 checkpoint class viability — Immutep's Phase 3 failure adds to mounting evidence that LAG-3 may not achieve blockbuster status, with implications for other programs in the class and investor appetite for next-generation immuno-oncology targets.
- Biosimilar development economics — The FDA's streamlined PK testing guidance could reduce per-program costs by $20 million, but the real test is whether development efficiencies translate into market entry given persistent barriers from patent thickets, rebate structures, and PBM dynamics that continue to limit biosimilar uptake.
- AI diagnostics spinout activity — Waiv's $33M financing and independence from Owkin may signal a broader trend of AI platform companies separating their diagnostics and therapeutics businesses to optimize commercial strategies.
Market Snapshot
- Vaccine sector regulatory environment: GSK's approval suggests the FDA may be moving past heightened caution around vaccine expansions, potentially opening pathways for other manufacturers with pending label expansion applications in respiratory and infectious disease categories.
- Checkpoint inhibitor development costs: Late-stage failures in the immuno-oncology space continue to exact heavy financial tolls, with Immutep's setback underscoring the risk premium investors demand for differentiated mechanism plays beyond proven PD-1 and CTLA-4 approaches.
- Biosimilar market expansion potential: The FDA's cumulative guidance overhaul — eliminating comparative efficacy studies in October and now streamlining PK testing — signals a structural shift in development economics, but biologics still account for 51% of U.S. drug spending despite only 5% of prescriptions, and structural barriers including patent cascades and rebate walls remain unresolved.